Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma.
Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin. However, no responses were achieved with 5-FU/iproplatin.
Petrelli
N J
NJ
Roswell Park Memorial Institute, Department of Surgical Oncology, Buffalo, NY 14263.
Creaven
P J
PJ
Herrera
L
L
Mittelman
A
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023359:iproplatin; D005472:Fluorouracil